Part 1 Basic Information
Name: Feng Shi
Address: School of Pharmacy, Jiangsu University, No. 301 Xuefu Road, Zhenjiang, Jiangsu 212013, China
Email: shifeng@ujs.edu.cn
Part 2 Personal Profile
Dr. Feng Shi is an Associate Professor and Master's Supervisor at the School of Pharmacy, Jiangsu University. His research focuses on traditional Chinese medicine (TCM) formulations and the development of novel TCM drugs. He has led four research projects funded by the Natural Science Foundation of Jiangsu Province, the Natural Science Foundation of Jiangsu Higher Education Institutions, the China Postdoctoral Science Foundation, and Jiangsu University, respectively. He has also participated in three projects supported by the National Natural Science Foundation of China and published over 20 high-quality research papers in academic journals. Dr. Shi has received numerous awards, including the First Prize of the Science and Technology Award of the China General Chamber of Commerce, the Third Prize of the Shanghai Science and Technology Progress Award, the Third Prize of the Science and Technology Award of the Chinese Medical Association, and the First Prize of the Special Contribution Award in Chinese Materia Medica and the Outstanding Scientific and Technological Innovation Award from Shanghai University of Traditional Chinese Medicine. He was selected for the "Science and Technology Deputy Township Chief Program" organized by the Organization Department of the Jiangsu Provincial Party Committee and served as Deputy Director of the Science and Technology Bureau of Quanshan District, Xuzhou, while concurrently serving as Deputy Director of the Administrative Committee of the Jiangsu Biotechnology and New Pharmaceutical Industrial Park. He also serves as an editorial board member of Pharmaceutics of Chinese Materia Medica, a textbook included in China's 13th Five-Year Plan for Higher Education.
Part 3 Education
·2010.09–2013.07, Shanghai University of Traditional Chinese Medicine, Chinese Materia Medica, Ph.D.
·2007.09–2010.07, Jiangsu University, Pharmaceutics, M.S.
·2003.09–2007.07, Jiangsu University, Pharmacy, B.S.
Part 4 Work Experience
·2019.05–Present, School of Pharmacy, Jiangsu University, Associate Professor and Master's Supervisor
·2013.10–2019.05, School of Pharmacy, Jiangsu University, Lecturer
Part 5 Research Interests
1. Research and Development of Traditional Chinese Medicine (TCM) Formulations
2. Research and Development of Novel TCM Drugs
3. Research on Nanoformulations
4. Research on Tumor Organoids
5. Research and Development of In Vitro Diagnostic (IVD) Reagents
Part 6 Research Achievements
6.1 Research Projects
•2018.09–2020.08 | "Study on the Therapeutic Mechanisms of Transumbilical Application of Warming-Interior Traditional Chinese Medicines for Inflammatory Bowel Disease" (Grant No. 18KJB360001) | Natural Science Foundation of Jiangsu Higher Education Institutions | Principal Investigator
•2018.07–2021.06 | "Study on the Dual Roles of Volatile Oils as Active Ingredients and Excipients and Their Mechanisms of Enhancing Skin Permeation in a Lipid-Based Transumbilical Drug Delivery System for Warming-Interior Traditional Chinese Medicines" (Grant No. BK20180866) | Natural Science Foundation of Jiangsu Province | Principal Investigator
•2014.09–2018.08 | "Preparation and Evaluation of Nanoformulations of Volatile Oils from Traditional Chinese Medicines" (Grant No. 14JDG165) | Research Startup Fund for Advanced Talents, Jiangsu University | Principal Investigator
•2014.05–2019.03 | "Development of a Lipid-Based Nanodrug Delivery System Tailored to the Unique Properties of Atractylodes macrocephala Volatile Oil" (Grant No. 2014M551523) | General Program of the China Postdoctoral Science Foundation | Principal Investigator
•2026.01–2028.01 | "Research and Development of a Traditional Chinese Medicine Delivery System for the Treatment of Radiation-Induced Pneumonitis" (Contract No. HX20260127) | Commissioned Research Project | Principal Investigator
•2025.12–2026.12 | "Flow Cytometric Phenotypic Characterization of Adipose-Derived Stem Cells and Identification of Brown and White Adipose Tissues" (Contract No. HX20260072) | Commissioned Research Project | Principal Investigator
6.2 Publications
1. Jinhe Li, Wei Ren, Feng Shi*, Banghu Wei, Weikang Wang, Jianmin Luo, Qinqin Liu. Atomic-scale defect engineering for photocatalytic CO2 upgrading to multi-carbon product: Mechanisms, design, and sustainability prospects[J]. Chemical Engineering Journal, 2026, 543: 178588. （SCI Q1，IF=12.5，Co-corresponding Author）
2. Lijuan Sun, Jinhe Li, Muhammad Adnan Qaiser, Feng Shi*, Weikang Wang, Qinqin Liu. Dynamic linkage conversion and engineering strategies in covalent organic frameworks: unlocking atomic-level control for enhanced photocatalytic activity and stability[J]. Coordination Chemistry Reviews, 2025, 543: 216918.（SCI Q1，IF=25.6，Co-corresponding Author）
3. Yanhai Xi, Zhen Zhang, Zixuan Zhao, Ba Qiu, Weiheng Wang, Guohua Xu, Zheru Sun, Feng Shi *, Wenkui Liang *, Jun Wu *. Injectable Thymosin β4-Modified Hyaluronic Acid Hydrogel with Exosomes for Stem Cell Homing and Neuronic–Angiogenic–Osteogenic Coupled Cranial Repair[J]. ACS Nano, 2025, 19(25): 22710-22724.（SCI Q1，IF=17.3，Co-corresponding Author）
4. Feng Shi, Mingjie Gong, Michael Adu-Frimpong, Xia Jiang, Xiaowen Wang, Qinyang Hua, Tingyuan Li, Jiaying Li, Jiangnan Yu, Elmurat Toreniyazov, Xia Cao, Qilong Wang, Ximing Xu. Isolation, Purification of Phenolic Glycoside 1 from Moringa oleifera Seeds and Formulation of Its Liposome Delivery System[J]. AAPS PharmSciTech, 2024, 25: 196.（SCI Q4，IF=4.0，First Author）
5. Feng Shi, Mengzhe Du, Qin Wang, Michael Adu-Frimpong, Chenlu Li, Xinyue Zhang, Hao Ji, Elmurat Toreniyazov, Xia Cao, Qilong Wang*, Ximing Xu*. Isoliquiritigenin Containing PH Sensitive Micelles for Enhanced Anti-Colitis Activity[J]. Journal of Pharmaceutical Sciences, 2024, 113: 918-929.（SCI Q3，IF=3.8，First Author）
6. Feng Shi, Wenxiong Yin, Michael Adu-Frimpong, Xiaoxiao Li, Xiaoli Xia, Weigang Sun, Hao Ji, Elmurat Toreniyazov, Wang Qilong, Xia Cao, Jiangnan Yu*, Ximing Xu*. In-vitro and in-vivo evaluation and anti-colitis activity of esculetin-loaded nanostructured lipid carrier decorated with DSPE-MPEG2000[J]. Journal of Microencapsulation, 2023, 40: 442-455.（SCI Q4，IF=3.0，First Author）
7. Junhua Zhang, Rui Bao, Faisal Raza, Hajra Zafar, Yingjie Qi, Yurui Geng, Ran Li, Jianqin Xue, Feng Shi*. Preparation and Evaluation of Onjisaponin B-Loaded Liposomes for Drug Delivery to Enhance Mitochondrial Function and Rescue Parkinson’s Disease by Activating Mitophagy[J]. Journal of Clinical Pharmacy and Therapeutics, 2023: 1262109.（SCI Q4，IF=2.1，Corresponding Author）
8. Feng Shi, Lin Chen, Yaping Wang, Jing Liu, Michael Adu-Frimpong, Hao Ji, Elmurat Toreniyazov, Qilong Wang, Jiangnan Yu, Ximing Xu*. Enhancement of oral bioavailability and anti-hyperuricemic activity of aloe emodin via novel Soluplus–glycyrrhizic acid mixed micelle system[J]. Drug Delivery and Translational Research, 2022, 12(3): 603–614.（SCI Q3，IF=4.617，First Author）
9. Ying Xu, Yulong Liu, Qi Liu, Shengzhe Lu, Xiaolin Chen, Wenrong Xu, Feng Shi*. Co-delivery of bufalin and nintedanib via albumin sub-microspheres for synergistic cancer therapy[J]. Journal of Controlled Release, 2021, 338: 705-718.（SCI Q1，IF=11.467，Corresponding Author）
10. Ying Xu, Lei Tang, Peng Chen, Mei Chen, Miaomiao Zheng, Feng Shi*, Yanchun Wang. Tumor-Targeted Delivery of Bufalin-Loaded Modified Albumin–Polymer Hybrid for Enhanced Antitumor Therapy and Attenuated Hemolysis Toxicity and Cardiotoxicity[J]. AAPS PharmSciTech, 2021, 22: 137.（SCI Q3，IF=4.026，Corresponding Author）
